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Abstract
Purpose The aim of the present study was to develop a stan-
dard operating procedure (SOP) for the collection, transport,
and storage of human cumulus cells, follicular fluid, blood
serum, seminal plasma, embryo culture supernatant, and em-
bryo culture supernatant control obtained within the IVF pro-
cess under approved protocols and written informed consent
from participating patients. The SOP was developed at the
Kinderwunsch Institut Schenk, Dobl, Austria, together with
Biobank Graz of the Medical University of Graz, Austria.
Methods The SOP provides comprehensive details of labora-
tory procedures and sampling of the different fluids within the
IVF process. Furthermore, information on sample coding, ref-
erences of involved laboratory techniques (e.g., oocyte re-
trieval with a Steiner-TAN needle), ethical approvals, and
biobanking procedures are presented.
Results The result of the present study is a standard operating
procedure.
Conclusions The SOP ensures a professional way for collec-
tion and scientific use of IVF samples by the Kinderwunsch
Institut Schenk, Dobl, Austria, and Biobank Graz of the
Medical University of Graz, Austria. It can be used as a tem-
plate for other institutions to unify specimen collection proce-
dures in the field of reproductive health research.
Keywords Biobanking . IVF . Follicular fluid . Steiner-TAN
needle . Standard operating procedure
Introduction
Infertility is a global phenomenon, affecting an estimated 48.5
million of reproductive-aged couples worldwide in 2010. The
overall burden of infertility has remained similar in estimated
levels and trends according to aWHO study published in 2012
[1]. This persisting problem of infertility explains the ever
increasing number of people receiving care in terms of
in vitro fertilization (IVF), the assisted reproductive technique
(ART), which is now existing for almost 40 years [2]. What is
known so far is that success in the IVF treatment depends on a
complex interplay of reproductive medicine and clinical em-
bryology. Changes in stimulation protocols were thought to
optimize the therapeutic outcome; however, clinical pregnan-
cy rates or baby take home rates did not increase as expected
[3]. Improving the process of IVF by different research ap-
proaches is tightly linked to state-of-the-art methods of sam-
pling, transporting, and storing of biological materials.
In terms of storage, biobanks have become indispensable
institutions for archiving biological materials. In their profes-
sional capacity, they do not only provide a vast amount of
different sample types, but are also in the ascendant to act as
research partners for upcoming scientific questions.
Biobanking studies in the field of reproductive medicine are
still a niche in IVF research, with only a few publications so
far [4, 5]. This unused scientific potential is possibly caused
Capsule The SOP provides comprehensive information on collection,
transport and storage of different body fluids within the IVF process to
assure comparability and sample reliability for state of the art molecular
analysis in future studies in the field of reproductive health research.
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by additional ethical hurdles concerning handling of embry-
onic specimens, cells, fluids, and tissues in terms of process-
ing and storage (i.e., cord blood, oocytes, etc.).
The mechanisms of collecting the samples are crucial for
the overall usefulness of the specimens for scientific research
and clinical purpose. Thus, standard operating procedures
(SOP) are required to standardize the different collections
and to facilitate comparability of international institutions of
reproductive medicine.
Here, we describe an SOP for collecting, processing, han-
dling, and storing samples derived from patients undergoing
IVF treatment comprising cumulus cells (CC), follicular fluid
(FF), blood serum (SR), seminal plasma (SE), embryo culture
supernatant (SU), and respective culture control media (SUC).
These fluids are promising candidates to investigate and corre-
late a variety of different parameters within the process of IVF.
A major advantage of the present SOP is the fact that follic-
ular fluid is collected with the Steiner-TAN-Needle, which al-
lows the collection of follicular fluid per oocyte instead of
pooling all the follicular fluids [6]. This technique allows linking
of one particular oocyte to the respective IVF outcome. Together
with modern IVF techniques like time-lapse culture systems [7]
and preimplantation genetic screening (PGS) [8], this SOP pro-
vides an efficient and powerfulmethod, addressing a broad range
of applications for different scientific questions and IVF studies.
In the recent years, follicular fluid (FF) has become a major
target for oocyte quality in human IVF. To limit embryo
Boverproduction,^ there is a trend to start the selection process
with the oocytes rather than with the already-fertilized oocytes
[9]. The follicular fluid comprises a variety of different pro-
teins including anti-apoptotic proteins and metalloproteinase-
and IGF-related proteins as well as other growth factors like
angiotensinogen (AGT), growth hormone receptor (GHR), or
hepatocyte growth factor-like protein (MST1) [10], thus serv-
ing as potential target for scientific questions. Besides blood
serum, seminal, and embryo culture supernatant, cumulus
cells have evolved to become interesting targets as predictors
of blastocyst formation and pregnancy success overall [11].
Methods and results
The SOP was established by the Kinderwunsch Institut
Schenk, Dobl, Austria, together with Biobank Graz [12] of
the Medical University of Graz, Austria, to facilitate future
international collaborations and to possibly improve the pro-
cess of IVF by gaining more insights into molecular mecha-
nisms and processes in early stages of embryogenesis. In the
different sections of the SOP, we outline the procedure from
responsibilities, via documents and references, to coding and
sampling of the different fluids. Furthermore, we essentially
included all of the materials and the respective companies
used and list the sampling processes in detail. Below, we refer
to details of the different SOP sections.
Purpose, scientific value, responsibilities, references,
abbreviations, materials, and sample collection approvals
Section 1 presents the purpose of the SOP, including information
on collected materials and how it was developed. Sections 2 and
3 state the scientific value and the scope. Section 4 comments on
the responsibilities of the involved directors/principal investiga-
tors and authorized staff members. In section 5, references and
documents are highlighted which contributed to the preparation
of the SOP. A list of all used abbreviations is found in section 6.
Section 7 reveals a list of materials, instruments, and reagents
with respective companies, for an accurate implementation of the
SOP. The section is divided in general equipment, instruments,
microscopes and related equipment, and culture media and em-
bryo culture equipment as well as tubes, dishes, and tips.
Section 8 shows the approval list for sampling, collecting, and
storage of bio-specimens, including ethical and patient approvals.
Coding, sample preparation, and storage and use
The coding system of the Kinderwunsch Institut Schenk is
shown in section 9. It serves as paradigm for other institutions,
including relevant information of the patient, type of sample,
and collection ID. Even if other coding systems are used, it is
suggested to include the essential information on the samples
and make sure that the sample type can be tracked and linked
to the appropriate patient record. In section 10, we provide
detailed protocols of sampling of blood serum, follicular fluid,
cumulus cells, seminal plasma, embryo culture supernatant,
and supernatant control. The section provides information on
authorities of performing the procedure, labeling of samples,
and storage at the biobank. Furthermore, the specific days of
sampling are provided in the SOP and in Fig. 1. Section 11
provides the sample usage with different methods of analyzing
proteomics and metabolomics.
During the whole procedure of the SOP, one has to keep in
mind that every sample has to be considered as potentially infec-
tious. Thus, wearing protective latex gloves is mandatory when
working with biological specimens at all time according to the
Level 2 criteria of the European Biosafety Association
(http://www.ebsaweb.eu/). It is not advisable to handle more
than one sample at the same time to avoid any possibility of
confusion and/or contamination. It is also necessary to use sepa-
rate sets of sterile instruments to avoid cross-contaminations.
Each institution may have their own regulations for both
transporting and handling human samples under Biosafety
Level 2 protocols (BSL2). However, the safety standards in the
respective institution should be ensured and followed. If institu-
tions do not have the ability to store their samples in a biobank, it
is recommended to store samples at−80 °C for long-term storage.
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1 Purpose
The present standard operating procedure (SOP)
describes the process of collecting, transporting, and
storing human body fluid samples (blood serum,
cumulus cells, follicular fluid, seminal plasma, and
embryo culture supernatants) at a biobank for re-
search purposes. The SOP was developed at the
Kinderwunsch Institut Schenk, Dobl, Austria, to-
gether wi th Biobank Graz of the Medical
University of Graz, Austria.
2 Scientific value
The storage of all samples enables retrospective, sci-
entific research, leading to a better understanding of pa-
thology and progression of diseases in the field of repro-
ductive biology. Furthermore, it permits optimization of
diagnostics and therapeutic approaches.
3 Scope
This procedure applies to blood serum, cumulus cells,
follicular fluid, seminal plasma, embryo culture superna-
tant, and supernatant control samples collected for re-
search in the field of reproductive biology.
4 Responsibilities
4.1 The Principal Investigator of the IVF institution and
the Director of Biobank have to maintain the standard
operating procedure.
4.2 Every sample collection operator involved in the pro-
cess of the SOP has to adhere to the procedure.
4.3 The Principal Investigator of the IVF institution and
the Director of Biobank have to ensure that the procedure
is followed and that all personnel adhere to the procedure.
5 References and documents
5.1 Rose BI, Laky D. A comparison of the Cook single
lumen immature ovum IVM needle to the Steiner-Tan
pseudo double lumen flushing needle for oocyte retrieval
for IVM. J Assist Reprod Genet 2013;30(6):855–60.
5.2 Steiner H-P. The effect of needle diameter on duration
of oocyte collection procedure. Hum Reprod 2011;
26(12):3495–3495
5.3 Sheldon E, Vo KC, McIntire RA, Aghajanova L,
Zelenko Z, Irwin JC, et al. Biobanking human endometri-
al tissue and blood specimens: standard operating proce-
dure and importance to reproductive biology research and
diagnostic development. Fertil Steril 2011;95(6):2120–
2122.e12.
5.4 UCSF Guide for the Research Use of Human
Biological Specimens: Collecting, Banking and Sharing
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& Protective latex gloves (biosafety level 2)
& Water-resistant pen
7.2 Instruments
Fig. 1 Schedule of sampling different fluids within the IVF process. The
graph shows the timeline of sampling blood serum (SR), seminal plasma
(SE), follicular fluid (FF), cumulus cells (CC), embryo culture
supernatant (SU), and control media (SUC). The number sign (#) stands
for a varying number of oocytes collected during the IVF process.
Asterisk indicates day of oocyte retrieval; double asterisks indicate day
of embryo transfer and/or embryo cryoconservation
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& Centrifuge EBA 20 (Andreas Hettich GmbH & Co.KG,
Germany)
& Fridge Medline (Liebherr-International Deutschland
GmbH, Germany)
& Incubator Forma (Thermo Fisher Scientific, USA)
& IVF workstation L24E with heating stage (K-SYSTEMS
Kivex Biotec A/S, Denmark)
& Needle 21G (Terumo Deutschland GmbH, Germany)
& Pioneer Pro Pump (Pioneer Pump Limited, UK)
& Pipette (0.5–10 μl; 100–1000 μl) (Eppendorf AG,
Germany)
& Steiner flush/valve (IVFETFLEX.com HandelsgmbH &
Co KG, Austria)
& Steiner-Tan Needle 17 gauge (IVFETFLEX.com
HandelsgmbH & Co KG, Austria)
& Sterile transfer pipette (VWR International GmbH,
Austria)
& Syringe 1 ml (Terumo Deutschland GmbH, Germany)
& Syringe norm-ject disposable (60 ml) (Henke-Sass, Wolf
GmbH, Germany)
& Tube warmer (Origio Clinical Monitoring GmbH,
Germany)
7.3 Microscope and equipment
& Cove r g l a s s 18 × 18 mm (Waldemar Kn i t t e l
Glasbearbeitungs GmbH, Germany)
& Object slide 76 × 26 × 1 mm (Engelbrecht Medizin- und
Labortechnik GmbH, Germany)
& Phase contrast microscope DMLS (×10, ×20, ×40 objec-
tive) (Leica Camera AG)
& Stereomicroscope Leica MZ95 (Leica Camera AG,
Germany)
& Stereomicroscope Nikon SMZ1500 (Nikon GmbH,
Austria)
7.4 Culture media and embryo culture equipment
& Embryoslide (Vitrolife AB, Sweden)
& F lu s h i ng med ium GM501 F lu sh (Gynemed
Medizinprodukte GmbH & Co.KG, Germany)
& Hyaluronidase (Gynemed Medizinprodukte GmbH &
Co.KG, Germany)
& Mineral oil (Gynemed Medizinprodukte GmbH &
Co.KG, Germany)
& Sperm air medium (Gynemed Medizinprodukte GmbH &
Co.KG, Germany)
& Universal culture medium (Gynemed Medizinprodukte
GmbH & Co.KG, Germany)
7.5 Tubes, dishes, and tips
& Centrifuge tube (15 ml) (VWR International GmbH,
Austria) [cat#: 525–0400]
& Culture dish (five wells) (MTG Medical Technology
Vertriebs-GmbH, Germany) [cat#: *3003177301]
& Eppendorf tips (0.1–10 μl) single packed (Eppendorf AG,
Germany) [cat#:30010019]
& Eppendorf tubes (1.5 ml) (Eppendorf AG, Germany)
[cat#:0030120086]
& IVF round dish 60 × 15 mm (VWR International GmbH,
Austria) [cat#:353652]
& IVF round dish cell culture dish 35 × 10 mm (VWR
International GmbH, Austria) [cat#:353801]
& Multipurpose beaker 100 ml sterile (Greiner Bio-One
International GmbH, Germany) [cat#:724473]
& Pipette tips (0.5–10 μl; 100–1000 μl) (Eppendorf AG,
Germany) [cat#:0030 000.919]
& Round bottom tube (15 ml) (VWR International GmbH,
Austria) [cat#:35–2001]
& Vacuette serum tube (Greiner Bio-One International
GmbH, Germany) [cat#:455071]
8 Sample collection approvals
8.1 Requirements:
8.1.1 Ethical review committee
8.1.1.1An authorization to work with human-derived samples
is required.
8.1.1.2 Apply for an ethic vote at your local ethical review
committee.
8.1.1.3 The ethical review committee will review the available
protocols.
8.1.1.4 Sampling cannot be realized without positive approval
of the ethical committee.
8.1.2 Patient(s)
8.1.2.1 For the collection of follicular fluid, seminal plasma,
blood serum, supernatant, and supernatant control, a positive-
signed written informed consent (IC) from each participating
patient is required.
8.1.2.2 The document is to be handed out and explained to the
patient prior to sampling.
8.1.2.3 The medical doctor or authorized staff ensures that the
patient thoroughly understands the informed consent before
signing it.
8.1.2.4 Staff from the patient management has to note the
respective person and add the IC to the patient chart.
8.1.2.5 A copy of the IC is handed over to the patient.
8.1.2.6 Refer to supplemental material or Biobank Graz




8.1.3 Medical data protection
8.1.3.1 Patient’s medical data protection has to be assured at
all time.
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8.1.3.2 The patient has to sign the informed consent.
8.1.3.3 The medical doctor or authorized staff has to sign that
he/she explained the IC to the patient.
8.1.3.4 Every patient participating gets an identification num-
ber (anonymization).
8.1.3.5 The identification number of the patient is deposited in
the QR code of every sample (pseudonymization).
8.1.3.6 From the moment, the samples are designated for
biobanking and leave the institution; it is only the IVF facility
which can backtrack the samples stored at a biobank.
8.1.3.7 Linkage to patients’ medical records is assured by the
IVF facility.
9 Coding
For tracing reasons, every sample gets an adhesive label
comprising a QR code and a human readable code. This
code was developed at Biobank Graz and is generated dur-
ing sample collection in an excel sheet with the TBarCode-
Add-In (TEC IT) for Microsoft Office. This coding system
is accomplished in theKinderwunsch Institut Schenk, Dobl,
Austria, and serves as a paradigm. It can be adjusted within
different institutions. The barcode is built as follows:
KIWI/123456/YYYYMMDD/FL/KI01/XXYQQ
Meaning of the individual elements:
KIWI Biobank abbreviation for Kinderwunsch
Institut Schenk
123456 Six-digit KIWI-ID of the patient
YYYY/MM/
DD
Date of sampling in format YYYY/MM/DD
(year, month, day)
FL Type of fluid (FL) sample (CC, cumulus cells;
FF, follicular fluid; SR, blood serum; SE,
seminal plasma; SU, supernatant; SUC, super-
natant control)
KI01 Collection ID (biobank), which grants
association between sample and collection of
one sender
XX double digit number, starting at 01 (01 = first
sample of one fluid type of one patient at a certain
date of sampling, 02 = second sample, etc.)
Y Samples with follicular fluid (FF): number of
oocytes.
All other samples = 0
QQ Samples with follicular fluid (FF): total
number of all follicles punctured
10 Sample preparation
10.1 Blood serum (SR)
10.1.1 Preparation
10.1.1.1 Blood collection is to be performed by a medical
doctor or authorized staff.
10.1.1.2 Print a label with name and sample ID of the
patient.
10.1.1.3 Inquire the full name and date of birth of the patient
and compare with the label to assure patient’s identity.
10.1.1.4 Note time of sampling and name of operating
person.
10.1.1.5Collect at least 4 ml venous blood in an 8-ml vacuette
tube (with serum separator).
10.1.1.6 Store sample for 30 min at 37 °C.
10.1.1.7 Use balance tubes and centrifuge samples at 1800g
for 10 min at room temperature.
10.1.1.8Collect at least 3 ml supernatant (=blood serum,
SR) in 15-ml tubes and store at 4 °C until transfer to
biobank.
10.1.1.9 Right before transport, put samples in a polystyrene
rack and deliver the box to a haulage service.
10.1.1.10 The haulage service assures a save transport to
biobank under a consistent-refrigerated temperature (4 °C).
10.1.1.11 Samples have to reach biobank within 24 h after
sampling.
10.1.1.12 Biobank assures validity of obtained SR samples by
checking the respective barcode.
10.1.1.13 Open SR samples manually and place into a
Hamilton sample carrier.
10.1.1.14 Fully automated Hamilton pipetting robot ML-
STAR splits obtained serum samples into six aliquots of
0.5 ml each.
10.1.1.15 Store SR samples at −80 °C in storage systems of
biobank for long-term storage.
10.1.2 Schedule of sampling
10.1.2.1 Women
10.1.2.1.1 Standard blood sampling (before hormone treat-
ment; day 2–3)
10.1.2.1.2 Day of oocyte retrieval (day 12–16)
10.1.2.1.3 Day of pregnancy test (∼10 days after embryo
transfer)
10.1.2.2 Men
10.1.2.2.1 Day of oocyte retrieval
10.2 Follicular fluid (FF) and cumulus cells (CC)
10.2.1 Preparation
10.2.1.1 Follicular fluid collection is performed by amedical
doctor or authorized staff.
10.2.1.2 Day before oocyte retrieval
10.2.1.2.1 Prepare 2 ml of flushing medium for every expect-
ed follicle and 2 ml of flushing medium to rinse the pump
system in a 60 ml disposable syringe and store it at 37 °C
overnight.
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10.2.1.2.2 Prepare a five-well culture dish with two drops
(=2× 25μl) of universal culture media per well and cover with
1 ml mineral oil.
10.2.1.2.3Mark the drops with numbers on top and bottom of
the culture dish.
10.2.1.2.4 Equilibrate the culture dish overnight at 37 °C,
5.5% CO2 in the incubator.
10.2.1.3 Day of oocyte retrieval
10.2.1.3.1 Prepare two 14-ml round tubes for every follicle
expected.
10.2.1.3.2 Prepare a five-well culture dish with warm flushing
media (37 °C).
10.2.1.3.3 Put the syringe with flushing medium in the Steiner
flush/valve station right before puncture and rinse the pump
system.
10.2.1.3.4 Note time of sampling and name of operating
person.
10.2.1.3.5 Assure patient’s identity before oocyte retrieval.
10.2.1.3.6 Puncture and flush every single follicle with the
Steiner-Tan Needle 17 gauge.
10.2.1.3.7 Collect follicular fluid and flushing medium sepa-
rately in pre-warmed and labeled round bottom tubes (at least
2–5 ml per follicle).
10.2.1.3.8 Put obtained fluids into sterile IVF round dishes
60 × 15 mm.
10.2.1.3.9 Examine FF and flushed medium for oocytes
with a stereo microscope on the heating stage of the
IVF workstation.
10.2.1.3.10 Culture single oocytes in labeled five-well culture
dish with flushing media.
10.2.1.3.11 Put FF back in a 14-ml round bottom tube.
10.2.1.3.12 Transfer FF into a 15-ml centrifuge tube with a
screw cap.
10.2.1.3.13 Store tubes at 4 °C until transfer to biobank.
10.2.1.3.14 Right before transport, put samples in a polysty-
rene rack and deliver the box to a haulage service.
10.2.1.3.15 The haulage service assures a save transport to
biobank under a consistent refrigerated temperature (4 °C).
10.2.1.3.16 Samples have to reach biobank within 24 h after
sampling.
10.2.1.3.17 Biobank assures validity of obtained FF samples
by checking the respective barcode.
10.2.1.3.18 Centrifuge samples (20 min, 867 rpm), collect
cumulus cells from the bottom of the tube and store at −80 °C.
10.2.1.3.19 Collect supernatant (=FF) and place into a
Hamilton sample carrier.
10.2.1.3.20 Fully automated Hamilton pipetting robot ML-
STAR splits obtained serum samples into four aliquots of
1 ml each.
10.2.1.3.21 Store FF samples at −80 °C in storage systems of
biobank for long-term storage.
10.2.1.4 IVF preparation
10.2.1.4.1 Perform IVF procedure with a stereo microscope
on the heating stage of the IVF workstation.
10.2.1.4.2 Take a dish cell culture dish 35 × 10 mm and put
three drops hyaluronidase with three drops sperm air next to
every hyaluronidase drop.
10.2.1.4.3 Remove cumulus cells by gently up and down pi-
petting of the oocyte in the hyaluronidase (maximum 40 s).
10.2.1.4.4 Every oocyte must be treated individually for ac-
curate tracking of the respective oocyte.
10.2.1.4.5 Wash oocyte by gently up and down pipetting of
the oocyte in the three drops of sperm air.
10.2.1.4.6 Transfer oocyte into five-well culture dish (pre-
pared with universal culture media and mineral
oil the day before).
10.2.1.4.7 Perform IVF or ICSI 1–4 h after oocyte
retrieval.
10.2.1.4.8 Culture single embryo in 25-μl universal culture
medium covered with mineral oil in embryo
slides 3–5 days.
10.2.1.4.9 Culture 25-μl universal culture medium in a sepa-
rate well in the same embryo slide (without embryo) as em-
bryo culture supernatant control (SUC) 3–5 days.
10.2.2 Schedule of sampling
10.2.2.1 Day of oocyte retrieval (day 12–16)
10.3 Seminal Plasma (SE)
10.3.1. Preparation
10.3.1.1 Collect ejaculate in sterile 100-ml beaker right before
oocyte retrieval.
10.3.1.2 Note time of sampling.
10.3.1.3 Print label with name and sample ID of the patient
and label a 15-ml centrifuge tube.
10.3.1.4 Transfer ejaculate into a 15-ml centrifuge tube with a
sterile transfer pipette.
10.3.1.5 Centrifuge 20 min at 3000 rpm.
10.3.1.6 Gently take off supernatant (1–3 ml) with a 1-ml
syringe.
10.3.1.7 Transfer to a second 15-ml centrifuge tube.
10.3.1.8 Centrifuge 20 min at 3000 rpm.
10.3.1.9 Collect supernatant in a third 15-ml centrifuge tube
(labeled).
10.3.1.10 Put a drop of the supernatant on an object slide and
check for successful removal of sperm cells with phase con-
trast microscope (×40 objective).
10.3.1.11Add another centrifugation step (20 min, 3000 rpm)
if there are still sperm cells in the sample.
10.3.1.12 Store tube at 4 °C until transfer to biobank.
10.3.1.13 Right before transport, put samples in a polystyrene
rack and deliver the box to a haulage service (4 °C).
10.3.1.14 The haulage service assures a save transport to
biobank under a consistent refrigerated temperature.
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10.3.1.15 Samples have to reach biobank within 24 h after
sampling.
10.3.1.16 Biobank assures validity of obtained SE samples by
checking the respective barcode.
10.3.1.17 Open SE samples manually and place into a
Hamilton sample carrier.
10.3.1.18 Fully automated Hamilton pipetting robot ML-
STAR splits obtained serum samples into 1-ml aliquots.
10.3.1.19 Store SE samples at −80 °C in storage systems of
biobank for long-term storage.
10.3.2. Schedule of sampling
10.3.2.1 Day of oocyte retrieval (day 12–16)
10.4 Embryo culture supernatant (SU) and control su-
pernatant (SUC)
10.4.1. Preparation
10.4.1.1 The collection of SU and SUC is performed by em-
bryologists or authorized staff.
10.4.1.2After end of the embryonal culture (=after embryonal
transfer and/or embryo cryoconservation) the culture superna-
tant (SU) and control (SUC) will be collected immediately
(refer to 10.2.1.4 for IVF preparation).
10.4.1.3 Note time of sampling.
10.4.1.4 Place embryo slide culture dish in a sterile work-
bench under a stereomicroscope.
10.4.1.5 Aspirate the mineral oil layer and gently absorb
approx. 20-μl SU with a pipette tip (0.1–10 μl).
10.4.1.6 Check culture supernatant for oil contaminations un-
der microscope and in case of contamination, aspirate remain-
ing oil.
10.4.1.7 Print a label with name and sample ID of the patient
and label a 1.5 ml Eppendorf tube.
10.4.1.8 Transfer SU in a 1.5-ml Eppendorf tube.
10.4.1.9 Change pipette tip and repeat the process with other
embryo culture wells.
10.4.1.10 Aspirate and transfer embryo culture control super-
natant SUC (cultivated without embryo; see 10.2.1.4.9) to a
1.5-ml Eppendorf tube.
10.4.1.11 Store tubes at 4 °C until transfer to biobank.
10.4.1.12 Right before transport, put samples in a polystyrene
rack and deliver the box to a haulage service.
10.4.1.13 The haulage service assures a save transport to
biobank under a consistent refrigerated temperature (4 °C).
10.4.1.14 Samples have to reach biobank within 24 h after
collection.
10.4.1.15 Biobank Graz assures validity of obtained SU and
SUC samples by checking the respective barcode.
10.4.1.16Open SU and SUC samples manually and place into
a Hamilton sample carrier.
10.4.1.17 Fully automated Hamilton pipetting robot ML-
STAR transfers samples into storage tubes (lobe tubes).
10.4.1.18 Store SU and SUC samples at −80 °C in storage
systems of biobank for long-term storage.
10.4.2. Schedule of sampling
10.4.2.1 Day 17–19 (day of embryo transfer and/or embryo
cryoconservation) after 3–5 days of embryo culture
11 Sample usage
11.1 Obtained samples can be analyzed with a variety of
techniques including proteomic and metabolomics
techniques.
Discussion
The Kinderwunsch Institut Schenk, Dobl, Austria, has started
to collect and store samples of FF, SE, SR, SU, and SUC in
2013. To date, more than 9000 different samples have been
collected and stored at Biobank Graz of the Medical
University of Graz. All samples from women and men under-
going IVF treatment have been approved for sampling and
storage. The high quality samples can be tracked and assured
by accurately following the SOP guidelines. This SOP serves
as a template for other institutions in the field of reproductive
health research to unify specimen collection procedureswithin
the process of IVF.
One major advantage of the present SOP is to routinely
collect samples, which would usually be designated as waste.
Hence, a comprehensive dataset can be obtained prospectively
for any type of retrospective study subsequently. The
dataset allows linkage of specific sample types to clinical
characteristics of the patients such as body mass index
(BMI), smoking habit, age, and type of ovarian stimulation
as well as pregnancy success and outcome.
Within the obtained dataset, follicular fluid is a parameter
with increasing importance for IVF treatment. As plasma ul-
trafiltrate, follicular fluid comprises signaling mediators,
mostly peptide hormones [13, 14], responsible for communi-
cation between granulosa cells, cumulus complex, and oocyte
and somatic compartment [15–18]. This signaling is manda-
tory for maintenance of oocyte integrity. In addition to the
ultrafiltrate, proteins can pass the follicular barrier, depending
on molecular weight and charge characteristics [19]. The fluid
components within the follicular fluid are potential sources for
biomarkers defining oocyte health. Different ways of sam-
pling and storage of follicular fluid are critical issues between
datasets and the comparability remains uncertain. The current
SOP addresses these issues and provides standardized sample
consistency, accuracy, and quality.
By now, the collection of samples obtained from the
Kinderwunsch Institut Schenk is unique in Austria and serves
as the major source for reproductive health research in
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Austria. To the best of our knowledge, no laboratory facility
collects follicular fluid per oocyte and stores this comprehen-
sive dataset of FF, SE, SR, SU, and SUC of patients receiving
IVF treatment in a biobank. The idea of storage of all these
materials refers to basic research in IVF and was invented to
gain knowledge of basic procedures in order to improve clin-
ical results and pregnancy outcome. So far, the samples col-
lected with the present SOP have already been used for scien-
tific purposes. Quantification of protein carbonyl groups as
oxidative stress parameter has been successfully analyzed in
seminal plasma, embryonal culture supernatant, and follicular
fluid [20]. Since the SOP was developed quite recently, there
is lots of unexploited potential for scientific questions.
The cooperation with Biobank Graz of the Medical
University of Graz enables investigators from all over the
world with straightforward access to stored samples. We pro-
vide this SOP for a standardized quality management to assure
good scientific practice and high quality of samples within
different institutions. Hence, comparability and sample reli-
ability can be guaranteed for state of the art molecular analysis
in future studies in the field of reproductive health research.
By following the SOP, sample handling and storage will be
standardized and research comparability in institutions
implementing the same procedures can be assured. This is a
big step forward towards sound and reliable research.
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